Evolus is a drug manufacturers - specialty & generic business based in the US. Evolus shares (EOLS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.24 – an increase of 4.48% over the previous week. Evolus employs 304 staff and has a trailing 12-month revenue of around $237.3 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $17.24 |
|---|---|
| 52-week range | $7.44 - $17.70 |
| 50-day moving average | $15.05 |
| 200-day moving average | $13.05 |
| Wall St. target price | $23.43 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.90 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17.24 from 2024-10-14
| 1 week (2024-10-09) | 2.80% |
|---|---|
| 1 month (2024-09-16) | 2.80% |
| 3 months (2024-07-16) | 43.43% |
| 6 months (2024-04-16) | 43.07% |
| 1 year (2023-10-16) | 107.71% |
|---|---|
| 2 years (2022-10-14) | 106.96% |
| 3 years (2021-10-15) | 124.77% |
| 5 years (2019-10-16) | 16.09% |
| Revenue TTM | $237.3 million |
|---|---|
| Gross profit TTM | $92.7 million |
| Return on assets TTM | -9.36% |
| Return on equity TTM | -861.68% |
| Profit margin | -22.43% |
| Book value | $0.31 |
| Market Capitalization | $1 billion |
TTM: trailing 12 months
We're not expecting Evolus to pay a dividend over the next 12 months.
Over the last 12 months, Evolus's shares have ranged in value from as little as $7.44 up to $17.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evolus's is 1.314. This would suggest that Evolus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Evolus, Inc. , a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.